151 related articles for article (PubMed ID: 9105473)
21. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes.
Inki P; Larjava H; Haapasalmi K; Miettinen HM; Grenman R; Jalkanen M
Eur J Cell Biol; 1994 Feb; 63(1):43-51. PubMed ID: 8005104
[TBL] [Abstract][Full Text] [Related]
22. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
Kumar-Singh S; Jacobs W; Dhaene K; Weyn B; Bogers J; Weyler J; Van Marck E
J Pathol; 1998 Nov; 186(3):300-5. PubMed ID: 10211120
[TBL] [Abstract][Full Text] [Related]
23. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer.
Wiksten JP; Lundin J; Nordling S; Lundin M; Kokkola A; von Boguslawski K; Haglund C
Int J Cancer; 2001 Jan; 95(1):1-6. PubMed ID: 11241302
[TBL] [Abstract][Full Text] [Related]
24. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY
Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
[TBL] [Abstract][Full Text] [Related]
25. Can syndecan-1 become a prognostic factor in solid tumors?
Oguri K; Okayama M
J Gastroenterol; 2004; 39(2):197-9. PubMed ID: 15074308
[No Abstract] [Full Text] [Related]
26. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma.
Shah L; Walter KL; Borczuk AC; Kawut SM; Sonett JR; Gorenstein LA; Ginsburg ME; Steinglass KM; Powell CA
Cancer; 2004 Oct; 101(7):1632-8. PubMed ID: 15378500
[TBL] [Abstract][Full Text] [Related]
27. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium.
Soukka T; Pohjola J; Inki P; Happonen RP
J Oral Pathol Med; 2000 Aug; 29(7):308-13. PubMed ID: 10947246
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of Ki-67 expression for patients with laryngeal squamous cell carcinoma primarily treated by total laryngectomy.
Acikalin MF; Oner U; Tel N; Paşaoğlu O; Cakli H; Colak E
Eur Arch Otorhinolaryngol; 2004 Aug; 261(7):376-80. PubMed ID: 14605812
[TBL] [Abstract][Full Text] [Related]
29. Effect of induction chemotherapy on changes of laminin and syndecan expression in oral squamous cell carcinomas: a prospective, randomized, clinicopathologic and immunohistochemical study.
Németh Z; Szigeti K; Máthé M; Szabó G; Velich N; Suba Z
J Craniofac Surg; 2005 Mar; 16(2):205-12. PubMed ID: 15750416
[TBL] [Abstract][Full Text] [Related]
30. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
Mukunyadzi P; Sanderson RD; Fan CY; Smoller BR
Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
[TBL] [Abstract][Full Text] [Related]
31. The role of syndecan-1 in malignancies.
Inki P; Jalkanen M
Ann Med; 1996 Feb; 28(1):63-7. PubMed ID: 8932508
[TBL] [Abstract][Full Text] [Related]
32. Assessment of syndecan-1 (CD138) and Ki-67 expression for differentiating keratoacanthoma and squamous cell carcinoma.
Lammoglia-Ordiales L; Toussaint-Caire S; Contreras-Barrera M; Fonte-Avalos V; Rodriguez-Carreón AA; Rivera-Macias S; Dominguez-Cherit J
J Drugs Dermatol; 2013 Mar; 12(3):e53-8. PubMed ID: 23545927
[TBL] [Abstract][Full Text] [Related]
33. Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penis.
May M; Burger M; Otto W; Hakenberg OW; Wieland WF; May D; Hofstädter F; Götz S; Niessl N; Fritsche HM; Birnkammer K; Gilfrich C; Peter J; Jain A; Koch S; Lebentrau S; Riedmiller H; Rössler W; Denzinger S; Brookman-May S; Gunia S
BJU Int; 2013 Aug; 112(4):E383-90. PubMed ID: 23305250
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma.
Boonkitticharoen V; Kulapaditharom B; Leopairut J; Kraiphibul P; Larbcharoensub N; Cheewaruangroj W; Chintrakarn C; Pochanukul L
Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1305-11. PubMed ID: 19075127
[TBL] [Abstract][Full Text] [Related]
35. Decreasing expression of glucose-regulated protein GRP78/BiP as a significant prognostic predictor in patients with advanced laryngeal squamous cell carcinoma.
Kaira K; Toyoda M; Shimizu A; Imai H; Sakakura K; Nikkuni O; Suzuki M; Iijima M; Asao T; Chikamatsu K
Head Neck; 2016 Oct; 38(10):1539-44. PubMed ID: 27312568
[TBL] [Abstract][Full Text] [Related]
36. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
Baba F; Swartz K; van Buren R; Eickhoff J; Zhang Y; Wolberg W; Friedl A
Breast Cancer Res Treat; 2006 Jul; 98(1):91-8. PubMed ID: 16636895
[TBL] [Abstract][Full Text] [Related]
37. Ki-67 immunostaining and prognosis in laryngeal cancer.
Krecicki T; Jeleń M; Zalesska-Krecicka M; Szkudlarek T
Clin Otolaryngol Allied Sci; 1998 Dec; 23(6):539-42. PubMed ID: 9884809
[TBL] [Abstract][Full Text] [Related]
38. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.
Fujiya M; Watari J; Ashida T; Honda M; Tanabe H; Fujiki T; Saitoh Y; Kohgo Y
Jpn J Cancer Res; 2001 Oct; 92(10):1074-81. PubMed ID: 11676858
[TBL] [Abstract][Full Text] [Related]
39. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical localization of syndecan-1 in normal and pathological human uterine cervix.
Inki P; Stenbäck F; Grenman S; Jalkanen M
J Pathol; 1994 Apr; 172(4):349-55. PubMed ID: 8207616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
